Bliss GVS Pharma Limited has informed the Exchange that Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Bliss GVS International PTE Ltd , Singapore, a wholly owned subsidiary of Bliss GVS Pharma Limited ( the Company ), has incorporated a wholly owned subsidiary namely Theralife Pharma Ltd , Nairobi, Kenya.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma Limited has informed the stock exchange that its wholly owned Singapore subsidiary, Bliss GVS International PTE Ltd, has incorporated a new wholly owned subsidiary named Theralife Pharma Ltd in Nairobi, Kenya. This disclosure was made under SEBI's Listing Obligations and Disclosure Requirements (Regulation 30). The move establishes a direct corporate presence in the African market through a two-step subsidiary structure. No financial details, capital infusion, or business purpose have been disclosed in this filing.
This is a strategic geographic expansion into East Africa, which could open new revenue opportunities for the pharma business over the long term. For shareholders, the immediate impact on the stock is likely neutral as no financial commitments or timelines have been shared yet.